Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution.
C. parapsilosis
Madrid
Rome
Y132F
fluconazole resistance
genotyping
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
01
02
2024
received:
22
12
2023
accepted:
07
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
ppublish
Résumé
Fluconazole-resistant Candida parapsilosis is a matter of concern. To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions. We selected fluconazole-resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility. Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild-type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild-type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole-resistance patterns found were: voriconazole-resistant (74.1%) or voriconazole-intermediate (25.2%), posaconazole-resistant (10%) and isavuconazole non-wild-type (47.5%). Fluconazole-resistant and voriconazole non-wild-type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non-wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L. We detected a recent clonal spread of fluconazole-resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city-specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non-susceptible to voriconazole and rarely posaconazole-resistant.
Sections du résumé
BACKGROUND
BACKGROUND
Fluconazole-resistant Candida parapsilosis is a matter of concern.
OBJECTIVES
OBJECTIVE
To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions.
PATIENTS/METHODS
METHODS
We selected fluconazole-resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility.
RESULTS
RESULTS
Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild-type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild-type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole-resistance patterns found were: voriconazole-resistant (74.1%) or voriconazole-intermediate (25.2%), posaconazole-resistant (10%) and isavuconazole non-wild-type (47.5%). Fluconazole-resistant and voriconazole non-wild-type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non-wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L.
CONCLUSIONS
CONCLUSIONS
We detected a recent clonal spread of fluconazole-resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city-specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non-susceptible to voriconazole and rarely posaconazole-resistant.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13706Subventions
Organisme : European Regional Development Fund
Organisme : Fondo de investigacion sanitaria (grants PI18/01155 and PI19/00074)
Organisme : Partially funded by Scynexis, Inc., Durham, NC, USA. PE (CPII20/00015) is a recipient of a Miguel Servet contract supported by FIS. AM (FI20/00089) holds a predoctoral grant from the FIS
Informations de copyright
© 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd.
Références
Escribano P, Guinea J. Fluconazole-resistant Candida parapsilosis: a new emerging threat in the fungi arena. Front Fungal Biol. 2022;3:1010782.
Daneshnia F, de Almeida Junior JN, Ilkit M, et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023;4(6):e470-e480.
Mesini A, Mikulska M, Giacobbe DR, et al. Changing epidemiology of candidaemia: increase in fluconazole-resistant Candida parapsilosis. Mycoses. 2020;63(4):361-368.
Siopi M, Tarpatzi A, Kalogeropoulou E, et al. Epidemiological trends of fungemia in Greece with a focus on candidemia during the recent financial crisis: a 10-year survey in a tertiary care academic hospital and review of literature. Antimicrob Agents Chemother. 2020;64(3):e01516-19.
Diaz-Garcia J, Gomez A, Machado M, et al. Candida genotyping of blood culture isolates from patients admitted to 16 hospitals in Madrid: genotype spreading during the COVID-19 pandemic driven by fluconazole-resistant C. parapsilosis. J Fungi (Basel). 2022;8(11):1228.
Alcoceba E, Gomez A, Lara-Esbri P, et al. Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. Clin Microbiol Infect. 2022;28(8):1113-1119.
Trevijano-Contador N, Torres-Cano A, Carballo-Gonzalez C, et al. Global emergence of resistance to fluconazole and voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic. Open Forum Infect Dis. 2022;9(11):ofac605.
Ramos-Martinez A, Pintos-Pascual I, Guinea J, et al. Impact of the COVID-19 pandemic on the clinical profile of candidemia and the incidence of fungemia due to fluconazole-resistant Candida parapsilosis. J Fungi (Basel). 2022;8(5):451.
Díaz-García J, Machado M, Alcalá L, et al. Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant C. parapsilosis spreading has gained traction in 2022. Antimicrob Agents Chemother. 2023;67(11):e0098623.
Mantecon-Vallejo MLA, Mesquida A, Ortiz MV, et al. Clonal spread of fluconazole-resistant C. parapsilosis in patients admitted to a referral hospital located in Burgos, Spain, during the COVID-19 pandemic. Mycoses. 2024;67(1):e13685.
Govrins M, Lass-Florl C. Candida parapsilosis complex in the clinical setting. Nat Rev Microbiol. 2024;22(1):46-59.
Routsi C, Meletiadis J, Charitidou E, et al. Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID-19 pandemic era. Antibiotics (Basel). 2022;11(6):771.
Asadzadeh M, Ahmad S, Al-Sweih N, Hagen F, Meis JF, Khan Z. High-resolution fingerprinting of Candida parapsilosis isolates suggests persistence and transmission of infections among neonatal intensive care unit patients in Kuwait. Sci Rep. 2019;9(1):1340.
Corzo-Leon DE, Peacock M, Rodriguez-Zulueta P, Salazar-Tamayo GJ, MacCallum DM. General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutation. Med Mycol. 2021;59(7):664-671.
Fekkar A, Blaize M, Bougle A, et al. Hospital outbreak of fluconazole-resistant Candida parapsilosis: arguments for clonal transmission and long-term persistence. Antimicrob Agents Chemother. 2023;95(5):e02036-20.
Thomaz DY, de Almeida JN, Sejas ONE, et al. Environmental clonal spread of azole-resistant Candida parapsilosis with Erg11-Y132F mutation causing a large candidemia outbreak in a Brazilian cancer referral center. J Fungi. 2021;7(4):259.
Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother. 2015;59(2):1030-1037.
Demirci-Duarte S, Arikan-Akdagli S, Gulmez D. Species distribution, azole resistance and related molecular mechanisms in invasive Candida parapsilosis complex isolates: increase in fluconazole resistance in 21 years. Mycoses. 2021;64(8):823-830.
Diaz-Garcia J, Gomez A, Alcala L, et al. Evidence of fluconazole-resistant Candida parapsilosis genotypes spreading across hospitals located in Madrid, Spain and harboring the Y132F ERG11p substitution. Antimicrob Agents Chemother. 2022;66(8):e0071022.
Guinea J, Meletiadis J, Arikan-Akdagli S, Giske K, Muehlethaler MC. Arendrup and the subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document E.Def 7.4. Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts. 2023.
Arendrup MC, Friberg N, Mares M, et al. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2020;26(11):1464-1472.
Marcos-Zambrano LJ, Gomez A, Sanchez-Carrillo C, et al. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect. Clin Microbiol Infect. 2020;26(11):1589-1592.
Mesquida A, Diaz-Garcia J, Sanchez-Carrillo C, Munoz P, Escribano P, Guinea J. In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method. Clin Microbiol Infect. 2022;28(1):140.e1-140.e4.
Guinea J, Arendrup MC, Canton R, et al. Genotyping reveals high clonal diversity and widespread genotypes of Candida causing candidemia at distant geographical areas. Front Cell Infect Microbiol. 2020;10:166.
Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12(5):418-425.
Thomaz DY, Del Negro GMB, Ribeiro LB, et al. A Brazilian inter-hospital candidemia outbreak caused by fluconazole-resistant Candida parapsilosis in the COVID-19 era. J Fungi (Basel). 2022;8(2):100.
Martini C, Torelli R, de Groot T, et al. Prevalence and clonal distribution of azole-resistant Candida parapsilosis isolates causing bloodstream infections in a large Italian hospital. Front Cell Infect Microbiol. 2020;10:232.
Chow NA, Gade L, Tsay SV, et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 2018;18(12):1377-1384.
de Groot T, Puts Y, Berrio I, Chowdhary A, Meis JF. Development of Candida auris short tandem repeat typing and its application to a global collection of isolates. MBio. 2020;11(1):e02971-19.
Arastehfar A, Daneshnia F, Hilmioglu-Polat S, et al. First report of candidemia clonal outbreak caused by emerging fluconazole-resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey. Antimicrob Agents Chemother. 2020;64(10):e01001-20.
Ceballos-Garzon A, Penuela A, Valderrama-Beltran S, Vargas-Casanova Y, Ariza B, Parra-Giraldo CM. Emergence and circulation of azole-resistant C. albicans, C. auris and C. parapsilosis bloodstream isolates carrying Y132F, K143R or T220L Erg11p substitutions in Colombia. Front Cell Infect Microbiol. 2023;13:1136217.
Magobo RE, Lockhart SR, Govender NP. Fluconazole-resistant Candida parapsilosis strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, South Africa. Mycoses. 2020;63(5):471-477.
Presente S, Bonnal C, Normand AC, et al. Hospital clonal outbreak of fluconazole-resistant Candida parapsilosis harboring the Y132F ERG11p substitution in a French intensive care unit. Antimicrob Agents Chemother. 2023;67(3):e0113022.
Singh A, Singh PK, de Groot T, et al. Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India. J Antimicrob Chemother. 2019;74(5):1260-1268.
Sagatova AA, Keniya MV, Wilson RK, Monk BC, Tyndall JD. Structural insights into binding of the antifungal drug fluconazole to Saccharomyces cerevisiae lanosterol 14alpha-demethylase. Antimicrob Agents Chemother. 2015;59(8):4982-4989.
Sagatova AA, Keniya MV, Wilson RK, Sabherwal M, Tyndall JD, Monk BC. Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14alpha-demethylase. Sci Rep. 2016;6:26213.
Healey KR, Kordalewska M, Jimenez Ortigosa C, et al. Limited ERG11 mutations identified in isolates of Candida auris directly contribute to reduced azole susceptibility. Antimicrob Agents Chemother. 2018;62(10):e01427-18.
Williamson B, Wilk A, Guerrero KD, et al. Impact of Erg11 amino acid substitutions identified in Candida auris clade III isolates on triazole drug susceptibility. Antimicrob Agents Chemother. 2022;66(1):e0162421.